Dyslipidemias and stroke prevention: Recommendations of the Study Group of Cerebrovascular Diseases of the Spanish Society of Neurology

Objective: We present an update of the Spanish Society of Neurology's recommendations for prevention of both primary and secondary stroke in patients with dyslipidaemia. Development: We performed a systematic review to evaluate the main aspects of the management of dyslipidaemias in primary...

Descripción completa

Detalles Bibliográficos
Autores: Palacio-Portilla, Enrique Jesús, Roquer, Jaume, Amaro, Sergio, Arenillas, Juan F., Ayo-Martín, Óscar, Castellanos, M., Freijo, María del Mar, Fuentes Gimeno, Blanca Eulalia, García-Pastor, Andrés, Gomis González, Maria, 1988-, Gómez-Choco, Manuel, López-Cancio, Elena, Martínez-Sánchez, Patricia, Morales, A., Rodríguez-Yáñez, Manuel, Segura, Tomás, Serena, Joaquín, Vivancos-Mora, José, Leciñana, María Alonso de, Grupo de Estudio de Enfermedades Cerebrovasculares de la Sociedad Española de Neurología
Tipo de recurso: artículo
Estado:Versión publicada
Fecha de publicación:2022
País:España
Institución:Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya)
Repositorio:Recercat. Dipósit de la Recerca de Catalunya
OAI Identifier:oai:recercat.cat:10230/54337
Acceso en línea:http://hdl.handle.net/10230/54337
http://dx.doi.org/10.1016/j.nrleng.2020.07.021
Access Level:acceso abierto
Palabra clave:Dislipidemia
Dyslipidaemia
Estatinas
Ictus
LDL cholesterol
LDL colesterol
Prevención
Prevention
Statins
Stroke
Descripción
Sumario:Objective: We present an update of the Spanish Society of Neurology's recommendations for prevention of both primary and secondary stroke in patients with dyslipidaemia. Development: We performed a systematic review to evaluate the main aspects of the management of dyslipidaemias in primary and secondary stroke prevention and establish a series of recommendations. Conclusions: In primary prevention, the patient's vascular risk should be determined in order to define target values for low-density lipoprotein cholesterol. In secondary prevention after an atherothrombotic stroke, a target value <55 mg/dL is recommended; in non-atherothombotic ischaemic strokes, given the unclear relationship with dyslipidaemia, target value should be established according to the vascular risk group of each patient. In both primary and secondary prevention, statins are the drugs of first choice, and ezetimibe and/or PCSK9 inhibitors may be added in patients not achieving the target value.

Similares en LA Referencia